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BACKGROUND: Half of anticancer drugs are predominantly excreted in urine. Dosage adjustment in renal insufficiency (RI) is, therefore,
a crucial issue. Moreover, patients with abnormal renal function are at high risk for drug-induced nephrotoxicity. The Belgian Renal
Insufficiency and Anticancer Medications (BIRMA) study investigated the prevalence of RI in cancer patients, and the profile/dosing of
anticancer drugs prescribed.
METHODS: Primary end point: to estimate the prevalence of abnormal glomerular filtration rate (GFR; estimated with the abbreviated
Modification of Diet in Renal Disease formula) and RI in cancer patient. Secondary end point: to describe the profile of anticancer
drugs prescribed (dose reduction/nephrotoxicity). Data were collected for patients presenting at one of the seven Belgian BIRMA
centres in March 2006.
RESULTS: A total of 1218 patients were included. The prevalence of elevated SCR (X1.2mg per 100ml) was 14.9%, but 64.0% had a
GFRo90mlmin
 1 per 1.73m
2. In all, 78.6% of treated patients (n¼1087) were receiving at least one drug needing dosage
adjustment and 78.1% received at least one nephrotoxic drug. In all, 56.5% of RI patients receiving chemotherapy requiring dose
reduction in case of RI did not receive dose adjustment.
CONCLUSIONS: The RI is highly frequent in cancer patients. In all, 80% of the patients receive potentially nephrotoxic drugs and/or for
which dosage must be adjusted in RI. Oncologists should check the appropriate dose of chemotherapeutic drugs in relation to renal
function before prescribing.
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The increased incidence of malignancies in patients with chronic
renal failure has been discussed since the middle 1970s (Sutherland
et al, 1977). One study reported that 188 organ tumours (6.7%) of
various pathologies were identified in 2817 patients who had
chronic renal failure (Cengiz, 2002). Although it is known to be
common in the general population (Jones et al, 1998), several
studies investigated the incidence of renal insufficiency (RI)
among cancer patients. Two studies (Launay-Vacher et al, 2004;
Dogan et al, 2005) observed a high prevalence of RI of B33 and
27%, respectively. A total of 50–60% of the 4684 cancer patients in
the IRMA-1 study had abnormal renal function (GFRo90),
whereas SCR levels were normal in most patients (Launay-Vacher
et al, 2007). These findings emphasise the high incidence of RI in
cancer patients. This is an important issue in clinical practise for
the handling of anticancer drugs in those patients. As B50% of all
anticancer drugs are excreted predominantly in the urine as
unchanged drug or active metabolite(s), any reduction in renal
clearance can result in accumulation of potentially toxic species
and overdosage. The dosage of chemotherapeutic agents used in
these patients with RI thus frequently requires dosage reduction to
avoid severe toxicities (Lichtman et al, 2007). Furthermore, using
potentially nephrotoxic anticancer drugs also will require specific
monitoring and, when available, specific prevention methods to
help reduce the risk for renal toxicity, especially in patients who
already have abnormal renal function. In fact, of the patients who
received an anticancer drug in the IRMA-1 study, 79.9% received
at least one drug that required a dosage adjustment or for which
there were no data for use in patients with RI and 80.1% received
at least one drug that was nephrotoxic (Launay-Vacher et al, 2007).
In this report, we present the results of the Belgian Renal
Insufficiency and Anticancer Medications (BIRMA) study, a large,
national cohort, multicentric, retrospective study that was
conducted to assess the prevalence of RI in cancer patients in
Belgium. Specific additional goals (not assessed in IRMA-1) were
to describe the profile and dosage of the anticancer drugs
prescribed according to the level of renal function, and to assess
the relation between renal function and anaemia, previous
chemotherapeutic treatments, history of renal disease, and
metastases.
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sMATERIALS AND METHODS
Study population
The BIRMA study included a total of 1218 solid cancer patients
presenting (either in hospital or as outpatients) in an oncology
department in one of the seven participating centres. The study
consisted of a retrospective patient data collection on the
period of March 2006 and was approved by the local ethical
committees. Patients were included regardless of disease patho-
logy, treatment (antineoplastic drugs used/to be used, line
of chemotherapy). Patients were excluded if they were aged o18
years, had acute renal failure, a diagnosis of haematological
disease or presented with end-stage renal disease that required
renal replacement therapy (either haemodialysis or peritoneal
dialysis).
Study design and assessments
The following data were collected for each patient: sex, age,
SCR, hemoglobinemia, type of tumour, metastasis (bone
and visceral), in/out patients, medical history of kidney disease,
nephrectomy, and previous and current anticancer drugs
prescribed. Doses of current anticancer drugs were also
collected. Estimations of renal function were made by esti-
mating glomerular filtration rate (GFR) with the abbreviated
Modification of Diet in Renal Disease (aMDRD) formula (Levey
et al, 1999).
GFRðmlmin 1per1:73m2Þ¼k 186 ðSCRÞ
 1:154 ðageÞ
 0:203
where k¼1 (men) or 0.742 (women), GFR indicates glomerular
filtration rate, and SCR is measured in mg per 100ml.
The aMDRD formula was chosen because it is more accurate
than Cockcroft–Gault formula (Kleber et al, 2007). Renal function
was staged in accordance with the clinical practise guidelines
published by the Working Group of the National Kidney
Foundation (NKF, 2002).
With regard to anticancer therapies prescribed to study
patients, the drugs that required dosage adjustment were
identified in accordance with their pharmacokinetics and avail-
able recommendations from two specific reference books on
drug dosage adjustment in patients with RI: Drug Prescribing
in Renal Failure: Dosing Guidelines for Adults, fifth edition
(Aronoff et al, 2007) and the Guide to Prescription Medications
for Patients with Renal Insufficiency, third edition (Launay-Vacher
et al, 2009).
Then, anticancer medications were classified as ‘yes’ when
adjustment was required, ‘no’ when adjustment was not necessary,
and ‘no data’ when no data were available in the literature. To
obtain profiles of anticancer therapies with regard to renal
tolerance, an exhaustive literature search was performed using
the National Institutes of Health PubMed database to identify
any potential renal side effects of the therapies. If, at least some
episodes of nephrotoxicity were identified in the literature search,
then the therapy was classified as ‘yes’ which indicated that the
drug was ‘potentially nephrotoxic’. Therapies were labelled ‘no’
when no such episodes were identified or when there were no
suggestion of potential renal toxicity.
Sub-group analyses on specific patients were performed. Renal
function was assessed on patients who had never received any
anticancer drugs before this visit (‘chemotherapy-naı ¨ve’ patients)
and those who had previously received at least one anticancer drug
(‘not chemotherapy-naive’ patients).
The link between anaemia and RI was also studied in
order to investigate the ‘renal part’ of the anaemia in RI cancer
patient.
End points
The primary end point was to estimate the prevalence of abnormal
GFR and RI in all cancer patients presenting in March 2006 in one
of the seven participating centres.
The secondary end point was to estimate the frequencies of
patients:
  Receiving at least one anticancer drug for which a dose
reduction is necessary in case of RI
  Receiving at least one potential nephrotoxic drug.
RESULTS
Patient demographics
In total, 1218 patients with various types of cancer were included
in the study from seven participating centres. Of these, 64.9% of
patients were women, and the mean age of all patients was 61.3
years. The most frequently occurring types of cancer in the study
population were breast (510 patients; 41.9%), colorectal (163
patients; 13.4%), lung (95 patients; 7.8%), prostate (91 patients;
7.5%), gynaecologic (79 patients; 6.5%), cerebral (49 patients,
4.0%). Gynaecologic cancer patients included ovarian and uterus
cancer patients. Table 1 shows the baseline characteristics of the
study cohort.
RI in BIRMA patients
Among the population, 12.5% had SCR41.2mg per 100ml and
48 patients (3.9%) had a known kidney disease according to the
medical records. In spite of this low proportion of patients with
elevated SCR and/or diagnosed kidney disease, a majority of
patients had in fact a decreased GFR when estimating the GFR with
the aMDRD formula: 64.0% had a decreased GFRo90mlmin
 1
per 1.73m
2 (Table 2). Such an estimation of renal function has
become the reference method in cancer patients (Kleber et al, 2007;
Barraclough et al, 2008; Holweger et al, 2008). Furthermore, when
focusing on the patients with a normal SCR (1023 patients), a high
prevalence of decreased GFR (665 patients, 65.0%) was also found,
meaning that the risk of missing a diagnostic of RI is important if
an estimation of the GFR is not performed.
As different tumour types can behave differently, and are treated
with different treatment modalities, we also looked at renal
function in the different tumour types. In the five main type of
cancer: breast, colorectal, lung, prostate, and gynaecologic 67.8,
59.5, 52.6, 62.6, and 69.6% had an aMDRDo90, respectively,
(Figure 1) confirming that all cancer patients are at risk for RI
whatever the type of cancer.
Anticancer drug profile
Among the BIRMA population, 1087 patients received an antic-
ancer drug at the time of the visit. These patients received 1852
prescriptions for anticancer drugs, resulting in a mean number of
1.7 drugs per patient.
The prescriptions included 62 different drugs (Table 3). Only a
minority of patients received biologicals because these drugs
(bevacizumab, sunitinib, sorafenib) were not reimbursed during
the study period. Furthermore, many patients received more than
one drug (Table 4). Of the 1852 prescriptions, 41.9% were
concerning drugs for which a dosage adjustment was necessary.
Furthermore, 10.2% of the prescriptions were concerning drugs for
which there were no data on their use in patients with RI, meaning
that the physicians did not know what to do in case of RI. Finally,
57.3% of the prescribed drugs were potentially nephrotoxic.
Of the 1087 patients, who received an anticancer drug, 78.8%
received at least one drug that required a dosage adjustment
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sor for which there were no data on their use in patients with
RI, and 78.1% received at least one drug that was potentially
nephrotoxic.
Among the 1087 treated patients, 581 patients (52.4%) with a
decreased GFR (or no GFR available) received at least one
potentially nephrotoxic drug (Table 5). Furthermore, these 581
patients received a total of 709 potential nephrotoxic drugs among
a total of 1067 prescriptions (nephrotoxic or not), meaning that
some patients received more than one nephrotoxic drug and that
66.4% (709 out of 1067 prescriptions) of the prescribed drugs in
this exposed population (581 patients) were potentially nephro-
toxic. However, the renal effects resulting of the exposition of these
drugs were not investigated.
Anticancer drug doses
When available, doses were collected for all the patients receiving
an anticancer drug at the inclusion visit. In all, 1286 doses were
collected for the 1852 prescriptions among the all population.
Because GFRo60 is the threshold for many anticancer drugs to
Table 2 Renal insufficiency among the BIRMA cancer patients according to the K/DOQI, KDIGO classification (NKF, 2002; Levey et al, 2005)
aMDRD–GFR
(mlmin
 1 per 1.73m
2)
General population
(n¼1218)
Chemotherapy-naı ¨ve
patients (n¼302)
Not chemotherapy-naı ¨ve
patients (n¼916)
Comparison: chemotherapy-naı ¨ve
vs not chemotherapy-naı ¨ve
X90, n (%) 358 (29.4) 122 (40.4) 236 (25.8) o0.0001
89–60, n (%) 583 (47.9) 122 (40.4) 461 (50.3) 0.002
59–30, n (%) 182 (14.9) 37 (12.3) 145 (15.8) 40.05
29–15, n (%) 11 (0.9) 3 (1.0) 8 (0.9) 40.05
o15, n (%) 3 (0.3) 2 (0.7) 1 (0.1) 40.05
No SCR available, n (%) 81 (6.7) 16 (5.3) 65 (7.1) 40.05
Abbreviations: aMDRD¼abbreviated Modification of Diet in Renal Disease formula; BIRMA¼Belgian Renal Insufficiency and Anticancer Medications; GFR¼glomerular filtration
rate; K/DOQI¼Kidney Disease Outcomes Quality Initiative; KIDGO¼Kidney Disease: Improving Global Outcomes.
Table 1 Characteristics of the BIRMA cancer patients at inclusion (March 2006)
General population
(n¼1218)
Chemotherapy-naı ¨ve
patients (n¼302)
Not chemotherapy-naı ¨ve
patients (n¼916)
Comparison: chemotherapy-naı ¨ve
vs not chemotherapy-naı ¨ve
Variables Mean±s.d. Mean±s.d. Mean±s.d. P-value
Age (years) 61.3±12.8 63.0±12.5 60.7±12.8 0.007
Weight (kg) 69.6±14.8 69.6±15.7 69.6±14.5 40.05
Height (cm) 166.1±9.1 167.5±9.0 165.7±9.1 0.01
Creatininemia (mg per 100ml) 0.94±0.52 0.96±0.74 0.92±0.42 40.05
aMDRD (mlmin
 1 per 1.73m
2) 82.7±35.9 85.4±26.4 81.7±38.6 0.05
Hemoglobinemia (g per 100ml) 11.9±1.7 11.9±1.7 11.9±1.7 40.05
Hematocrit (%) 35.8±4.9 35.3±4.9 36.0±4.9 40.05
Number of
patients (%)
Number of
patients (%)
Number of
patients (%) P-value
Bone metastasis 396 (32.5) 36 (11.9) 360 (39.3) o0.0001
Visceral metastasis 463 (38.0) 87 (28.8) 376 (41.1) 0.0001
Known kidney disease 48 (3.9) 20 (6.6) 28 (3.1) 0.006
Nephrectomy 22 (1.8) 3 (1.0) 19 (2.1) 40.05
Abbreviations: aMDRD¼abbreviated Modification of Diet in Renal Disease formula; BIRMA¼Belgian Renal Insufficiency and Anticancer Medications.
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Figure 1 Renal insufficiency for the whole BIRMA population and for the five main types of cancer.
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sconsider dose modification, a specific analysis was performed for
RI patients receiving chemotherapy for which a dose adjustment
may be considered. In all, 161 prescriptions among 147 patients
needed a dose reduction according to the level of renal function.
Doses were missing for 41 prescriptions (39 patients). Anticancer
drugs doses were compared with recommended dosage in RI
patients (Launay-Vacher et al, 2009). For patients receiving
carboplatin, the doses were calculated with the Calvert and
Chatelut formulae (Calvert et al, 1989; Chatelut et al, 1994).
Among the prescriptions (120) and patients (108), 46.6–48.3%
of the prescription for 50–51.9% of the patients did not have
an adequate dose according to their renal function and depen-
ding on the formula used to calculate carboplatin doses. 34–44
(28.3–36.7%) prescriptions were overdosed according to renal
function. These patients were, therefore, exposed to renal and
extra-renal toxicities induced by an overdose. These overdosed
prescriptions included: zoledronate (19 prescriptions), carboplatin
(6–16 prescriptions according to Chatelut and Calvert formulae,
respectively), cisplatin (5), capecitabine (3), and etoposide (1).
Furthermore, 32 additional patients without an evaluation of renal
function received 36 prescriptions for which a dose adjustment
would have been necessary in case of RI.
Anaemia
Anaemia is common in patients with cancer and is a frequent
complication of myelosuppressive chemotherapy (Schwartz, 2007).
In all, 55.3% of BIRMA patients presented anaemia (WHO criteria)
and 26.9% had a hemoglobinemiao11g per 100ml. In all, 6.2%
received erythropoiesis-stimulating agents.
Table 3 Anticancer drugs most often prescribed to patients in the study
INN No. of prescriptions Percent of prescription (%) Need for dosage adjustment in RI Potential nephrotoxicity
Fluorouracil 248 13.6 No No
Zoledronate 220 12.1 Yes Yes
Docetaxel 114 6.2 Yes No
Cyclophosphamide 101 5.5 Yes No
Epirubicin 94 5.2 No SC
Trastuzumab 92 5.0 ND SC
Gemcitabine 90 4.9 No Yes
Cisplatin 89 4.9 Yes Yes
Carboplatin 70 3.8 Yes Yes
Paclitaxel 63 3.5 No SC
Oxaliplatin 61 3.3 No Yes
Irinotecan 53 2.9 No Yes
Doxorubicin 52 2.8 No SC
Capecitabin 47 2.6 Yes No
Letrozole 42 2.3 No No
Tamoxifen 41 2.2 No SC
Ibandronate 35 1.9 Yes No
Vinorelbine 32 1.8 Yes No
Exemestane 30 1.6 No No
Temozolomide 22 1.2 ND No
Cetuximab 18 1.0 No Yes
Other 238 12.9 Yes: 28.2% Yes: 100 prescriptions
ND: 31.5% ND: 18 prescriptions
No: 40.3% No: 100 prescriptions
Total 1852 100 Yes: 41.8% Yes: 1043 prescriptions
ND: 10.2% ND: 18 prescriptions
No: 47.9% No: 791 prescriptions
Abbreviations: INN¼international non-proprietary name; ND¼no data available in the literature for use in patient with RI or for nephrotoxicity; RI¼renal insufficiency;
SC¼sparse cases. Other: anticancer drugs that were prescribed in o1% of patients in the study (decreasing number of prescriptions): bevacizumab, gosereline, etoposide,
fulvestrant, methotrexate, topotecan, anastrozole, dacarbazine, vinblastine, erlotinib, vinflunine, mitoxantrone, bicalutamide, mitomycine, megestrole, pamidronate, imatinib,
ifosfamide, vaccine, bleomycin, lomustin, estramustin, fotemustin, gefitinib, leuproreline, octreotide, hydroxycarbamide, pemetrexed, triptoreline, sunitinib, panitumumab,
thyrixine, cyproterone, carmustine, rituximab, streptozocine, matuzumab, sorafenib, lanreotide, ipilimumab.
Table 4 Anticancer drugs associations most often prescribed to patients in the study
Main anticancer drugs
associations
No. of
prescriptions
Percent of
prescription (%)
Need for dosage
adjustment in RI
Potential
nephrotoxicity
Cyclophosphamide–epirubicin–fluorouracil 80 7.4 Yes–No–No No–SC–No
Fluorouracil–oxaliplatine 53 4.9 No–No No–Yes
Fluorouracil–irinotecan 36 3.3 No–No No–Yes
Carboplatin–paclitaxel 27 2.5 Yes–No Yes–SC
Letrozole–zoledronate 26 2.4 No–Yes No–Yes
Tamoxifen–zoledronate 23 2.1 No–Yes SC–Yes
Cisplatine–gemcitabine 21 1.9 Yes–No Yes–Yes
Cisplatine–fluorouracil 20 1.8 Yes–No Yes–No
Exemestane–zoledronate 16 1.5 No–Yes No–Yes
Docetaxel–zoledronate 14 1.3 Yes–Yes No–Yes
Abbreviations: RI¼renal insufficiency; SC¼sparse cases.
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sAnaemia in cancer patients may be the result of several different
etiologies. Particularly, it could result from a direct haemato-
toxicity of chemotherapy or be of a renal origin in patient
with concomitant RI (and cancer disease). In BIRMA patients, we
studied the potential effect of RI (GFRo60) on hemoglobinemia and
found that RI was a risk factor for anaemia (OR¼1.54, (1.11; 2.13)).
Furthermore, the anaemia was more frequent in RI patients with a
GFRo60 then in patients with a GFR X60. (66.2 vs 56.0%, P¼0.01).
On performing the same analysis of the 302 ‘chemotherapy-
naive’ patients, we found that the prevalence of anaemia was still
higher in RI patients (77.5 vs 59.5%, P40.05), but not significantly
(OR¼2.04, (0.96; 4.37)). Same trends were found when focusing
on the 916 ‘not chemotherapy-naive’ patients, but this time, RI was
linked to anaemia in this population (OR¼1.5, (1.04; 2.16)) with
a prevalence of anaemia higher in RI patients (GFRo60) vs in
patients without RI (64.5 vs 54.8%, respectively, P¼0.03).
RI and medical history of chemotherapy
Among the 1218 BIRMA patients, 302 patients (24.8%) had never
received any anticancer drugs before this visit (‘chemotherapy-naive’
patients) and 916 (75.2%) patients had previously received at least
one anticancer drug (‘not chemotherapy-naı ¨ve’ patients; Table 1).
When assessing the prevalence of RI according to the anticancer
drug history, ‘not chemotherapy-naive’ patients had a higher
prevalence of RI than ‘chemotherapy-naı ¨ve’ patients. In all, of
54.3% of the 302 ‘chemotherapy-naive’ patients had a decreased
GFR (o90) vs 67.1% for ‘not chemotherapy-naive’ patients
(Po0.0001; Table 2).
Bone/visceral metastasis
We also investigated the frequencies of RI according to metastasis.
The prevalence of decreased GFR (o90) was higher in patients
presenting a bone metastasis than in patients without (69.4 vs
61.3%, P¼0.006). This high prevalence was also observed between
patients with visceral metastasis and without (69.5 vs 60.5%,
P¼0.001).
Three intravenous bisphosphonates were prescribed in BIRMA:
ibandronate, pamidronate, and zoledronate. Most patients pre-
senting with bone metastases received zoledronate (220 patients;
Table 3). Among them, 67.3% presented a decreased GFR and
50.9% had RI.
RI and multivariate analysis
As some factors were found to influence renal function in BIRMA
cancer patients, two logistic regressions were performed upon the
relationship between RI (GFRo90 and GFRo60) and multiple
factors (same factors for both analyses). The factors entered into
the analysis included gender, age, bone/visceral metastasis,
medical history of chemotherapy (Table 6). Age, gender, bone
metastasis, and medical history of chemotherapy were found to be
risk factors for RI or abnormal GFR.
DISCUSSION
In this study, we found that RI is highly frequent in cancer
patients. However, the prevalence of RI is routinely under-
estimated in clinical practice when physicians most often base
their diagnosis on SCR measurements only. In all, 7% of our
patients had no report of SCr determination in their file, but
they were probably patients only seen for a routine control
(for instance nadir control). It is crucial to outline that SCR is not
appropriate for evaluating renal function, but that GFR is
calculated by formulas such as aMDRD, also in patients with a
normal SCR and even on regular time points in patients coming
for a routine consultation without injection of anticancer
drugs, because there are still exposed to renal and extra renal
toxicity of non-anticancer drugs prescribed for other pathologies.
For example, 46.7% of the 120 patients with a GFRo60 and for
which drug dosages were available in the medical file received
at least one drug with an inappropriately dose according to renal
function.
In patients with stage-2 RI, potential drug nephrotoxicity is the
main issue. Many studies have demonstrated that pre-existing
abnormal renal function is a risk factor for drug-induced
nephrotoxicity (Nikolsky et al, 2005). As a result, in those patients
with mildly decreased renal function, anticancer drugs, antineo-
plastic, or supportive care, physicians should be aware of the
potential risk of nephrotoxicity, and take precautions if possible.
If the use of nephrotoxic drug is necessary, it is crucial to adapt
the dose, when necessary, according to the renal function and to
follow the guidelines for the management of renal toxicity if
available, such as for cisplatin (Lichtman et al, 2007), for example.
The BIRMA patients with a decreased GFR received a mean of
1.2 nephrotoxic anticancer drug. Furthermore, some patients
received nephrotoxic associations (Table 4), which expose them
to a higher iatrogenic renal risk (cisplatineþgemcitabine, for
example). Consequently, it is crucial to avoid (when possible),
nephrotoxic combinations of anticancer drugs and non-anticancer
drugs. As we did not collect data on other medication, such as pain
killers, for which some drugs are clearly nephrotoxic, it is difficult
to know how many nephrotoxic drugs (anticancer and others)
these patients received in total. We thus may consider that the
Table 5 Profile of anticancer drugs (chemotherapy, support
treatmentsy) according to the renal function
Number of patients with at least
one drug: (n¼1087)
aMDRD–GFR
Which is potentially
nephrotoxic
For which a dose
adjustment is required
(mlmin
 1 per 1.73m
2) Labelled ‘yes’ or ‘ND’ Labelled ‘yes’ or ‘ND’
X90, n (%) 268 (24.7) 253 (23.3)
89–60, n (%) 408 (37.5) 430 (39.6)
59–30, n (%) 120 (11.0) 122 (11.2)
29–15, n (%) 6 (0.6) 5 (0.5)
o15, n (%) 0 (0.0) 0 (0.0)
No Data, n (%) 47 (4.3) 44 (4.1)
Abbreviations: aMDRD¼abbreviated Modification of Diet in Renal Disease formula;
GFR¼glomerular filtration rate; ND¼no data available.
Table 6 Predictions of abnormal GFR and of renal insufficiency
(multivariate analysis)
Variables Odds ratio, (CI95%) P-value
Predictions of abnormal GFR (GFRo90mlmin
 1 per 1.73m
2)
Gender 2.20 (1.65, 2.91) Po0.0001
Age 1.06 (1.04, 1.07) Po0.0001
Bone metastasis 1.12 (0.90, 1.43) P40.05
Visceral metastasis 0.84 (0.62, 1.14) P40.05
Medical history of chemotherapy 2.09 (1.53, 2.86) P¼0.001
Predictions of renal insufficiency (GFRo60mlmin
 1 per 1.73m
2)
Gender 1.73 (1.21, 2.47) P¼0.003
Age 1.08 (1.06, 1.10) Po0.0001
Bone metastasis 1.46 (1.03, 2.6) P¼0.04
Visceral metastasis 0.89 (0.63, 1.24) P40.05
Medical history of chemotherapy 1.36 (0.94, 2.11) P40.05
Abbreviations: CI¼confidence interval; GFR¼glomerular filtration rate.
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sexposition to all kind of nephrotoxic drug was underestimated in
our patients.
The BIRMA was not designed to find the aetiology of RI in
cancer patients. However, it provided us with some hypotheses and
potential contributing factors. The lower prevalence of RI in
‘chemotherapy-naı ¨ve’ patients compared with ‘not chemotherapy-
naı ¨ve’ patients, of which many are potentially nephrotoxic,
suggests a possible role of anticancer drugs. Both univariate and
multivariate analysis found that medical history of chemotherapy
was a risk factor for abnormal GFR. A causal relationship is
difficult to assess based on our data, as other factors (e.g.,
increased use of pain killers, disease progression with obstructive
renal problemsy) can contribute as well. Furthermore, patients
presenting with bone metastasis had a higher prevalence of RI, but
also here the exact causality is difficult to make. It seems plausible
that potentially nephrotoxic chemotherapy at least contribute in
some part to the declining renal function in cancer patient with
progressive disease.
In the BIRMA study, 50.9% of the 220 patients under
zoledronate presented a GFRo60 (vs 16.1% in the whole
population, 22.5% in the 396 bone metastasis patients, 40.0% in
the 35 patients with ibandronate, and 66.7% in the 6 patients with
pamidronate). It is possible that renal toxicity induced by
nephrotoxic anticancer drug, such as zoledronate, adds to the
high prevalence of RI, but many other factors can contribute as
mentioned previously.
As some factors were not collected in BIRMA patients, such as
blood losses, radiation, nutritional deficiencies, inflammation
(Schwartz, 2007), it is difficult to exactly quantify the ‘renal part’
of anaemia. Anaemia can have a negative impact on physical
and psychosocial function, and quality of life in patients with
cancer (Schwartz, 2007), and is a negative prognostic factor
(Harper and Littlewood, 2005), so it is important to first diag-
nose and characterise anaemia, and second, to correct it accor-
ding to the available guidelines (Aapro and Link, 2008) and to
adapt the dose of anticancer drugs in RI patients in order to
prevent both renal and extra renal (such as haematoxicity) side
effects.
In the BIRMA study, the prevalence of RI was higher than that
reported in IRMA-1 study. The prevalence of a decreased GFR
(o90) was significantly higher among the Belgian patients than in
the French ones (64.0 vs 52.9%, Po0.0001; Launay-Vacher et al,
2007) and in the study conducted by Dogan et al (2005). These
differences between the prevalence of RI between the three studies
may have resulted from differences in patient populations. For
example, there were a high proportion of patients with breast
cancer in BIRMA study, whereas Dogan et al had a high number
of patients with gastrointestinal tumours. Furthermore, both
Dogan and IRMA-1 studies included younger patients than the
patients studied in BIRMA (mean age, 52, 58 and 61 years,
respectively).
CONCLUSION
Many anticancer drugs can cause RI, and many anticancer drugs
require dose adaptation in RI. It may not be always possible not to
use potentially nephrotoxic drugs (Launay-Vacher et al, 2008).
However, it remains very important to be aware of the renal
function of patients who receive such drugs, and to monitor renal
function on a regular basis, before each course of therapy during
treatment.
Our study shows that a significant number of RI patients
receiving chemotherapy requiring dose reduction in case of RI did
not receive dose adjustment. Oncologists should check the
appropriate dose of chemotherapeutic drugs in relation to actual
renal function before prescribing to their patients.
Furthermore, in those patients who require nephrotoxic antic-
ancer drugs, and especially those with baseline decreased renal
function, cautious selection, and analysis of concomitant drugs
should be performed. For example, non-steroidal anti-inflamma-
tory drugs, if possible, should be avoided, as they may increase the
renal toxicity of chemotherapy.
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